Grant funders

Michael J. Fox Foundation

Private foundation, New York

Also known as MJFF, Michael J. Fox Foundation for Parkinson's Research

United States
Follow this funder Website

Create a free account and its new calls come to you by email.

Open calls 0
Given in 2025 -
Typical grant $301k Middle half $113k to $893k
New grantees in 2025 34% first grant from this funder

Giving by year

34% of 2025 grantees were new to this funder 43% of grantees are funded again within three years

Amount and number of grants we hold records for in each year, which can be less than everything the funder gave. The current year is incomplete.

Where it gives

California 73 grants · typical $826k
Massachusetts 69 grants · typical $300k
New York 54 grants · typical $239k
Maryland 24 grants · typical $372k
Pennsylvania 23 grants · typical $926k
Illinois 21 grants · typical $375k
Texas 20 grants · typical $181k
London 17 grants

All years we hold. Grants with no recorded place are left out.

Latest grants made

Indiana University Investigating the Role of Immune Cell Exhaustion (ICE) and Biological Immune Aging (BIA) in PD Risk and PD Heterogeneity 1 Jan 2026
University of Murcia Multimodal Machine Learning Models for Predicting Lewy Body Pathology Using Post-mortem Brain Data 1 Jan 2026
University of north carolina at chapel hill Characterization of Constrained Peptides Targeting LRRK2 and Downstream Signaling 1 Jan 2026
University of maryland baltimore Inhibition of Acid Ceramidase as a Therapy for GBA1-associated PD 1 Jan 2026
University of copenhagen Connecting the Environmental Exposome to PD Risk and Disease Pathology 1 Jan 2026
IRCCS Istituto delle Scienze Neurologiche di Bologna PWR-PD (“Power-PD”): Personalized Wearable-based Rehabilitation for Parkinson’s Disease 1 Jan 2026
Lund university Defining Functional Heterogeneity Within the Subthalamic Area and Its Relevance for Psychiatric Symptoms of PD 1 Jan 2026
Washington University School of Medicine Precision Mapping of Somato-Cognitive Action Network (SCAN) Pathophysiology in Parkinson’s Disease Gait Disturbance 1 Jan 2026
AcureX Therapeutics Corporation Preclinical Efficacy Studies for CU-13001, a 15-Lipoxygenase Inhibitor for the Treatment of Parkinson’s Disease 1 Jan 2026
Stanford university Blood-based Signatures of CSF Synuclein SAA Positivity 1 Jan 2026

Data: Source: Internal Revenue Service, Form 990-series e-file data. (Public IRS data); Data from OpenAlex (CC0). (CC0 1.0); Data from OpenAlex (CC0) (CC0 1.0)